Biotech
Statins could help prevent cardiovascular diseases
A study shows the risk of having a cardiovascular disease can be lessened through statins.
Cardiovascular diseases, also known under the acronym CVD, are a group of conditions that affect the heart or blood vessels. This range of conditions includes heart failure, carditis, stroke, hypertensive heart disease, cardiomyopathy, heart arrhythmia, valvular heart disease etc.
Risk factors for cardiovascular disease are obesity, inactivity, high blood pressure or high cholesterol, immoderate smoking or alcohol consumption, as well as poor nutrition. Experts advise that the prevention of all cardiovascular diseases must include a healthy diet and everyday exercise. However, for people at the age between 40 and 50 years who are at risk for cardiovascular disease the use of a statin along with a healthy nutrition and exercise could be also a way to fight against stroke or heart arrhythmia, among other heart conditions.
Experts from the U.S. Preventative Services Task Force who analyze all the latest scientific evidence recommend people with high blood pressure, cholesterol or diabetes and those who have a greater chance of having a heart attack or stroke to exercise more, eat healthily but also to use a statin for preventing cardiovascular disease.
HMG-CoA reductase inhibitors, also known as statins, are a group of lipid-lowering medications. Studies and researches have found statins helpful in reducing the risks of cardiovascular diseases. Evidence have shown that statins could help treat CVD in the early stages.

-
Fintech1 week ago
Fintech Companies Have Made Banking Accessible to 74% of People in Latin America
-
Impact Investing1 day ago
Edison’s 2024 Results Decline, but Sustainability and Renewables Drive Growth
-
Business1 week ago
TopRanked.io Weekly Digest: What’s Hot in Affiliate Marketing [InboxAlly Affiliates Review]
-
Biotech2 weeks ago
KOA Biotech closes a 2M round led by Swanlaab
You must be logged in to post a comment Login